Startups and Big Pharma companies alike are considering India as an alternative to working with China. Is it safe to do business with India? Let's do a deep dive, with insights from American and Indian attorneys.
Learn about a more human-relevant platform that enables researchers to assess the trafficking and killing efficiency of immunotherapy as well as the proof-of-concept of immuno-oncology co-therapy.
Fast-track RNA-LNP development, streamline screening with off-the-shelf ionizable lipid mixes, and utilize validation strategies to generate reproducible and scalable LNPs for lead candidates.
Article | By Dan Bowles, Mike Johnson, and Brian Swierenga, Cambrex
To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.
Discover a protein L affinity chromatography resin that is well suited for use in biomanufacturing and offers increased binding capacities compared to other resins.
